| Biomarker ID | 919 |
| PMID | 22564540 |
| Year | 2012 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B] |
| Type of Biomarker | Diagnostic |
| Cohort | 180 men with first negative prostate biopsy were taken into the study and patients with inadequate information were removed. Patients were randomly assigned into Two groups in 1:1 ratio. Group A (n=64) were subjected to TRUS-guided prostate biopsy, whereas patients in Group B (n=64) were submitted to a multiparametric MRI examination and then to a second TRUS-guided prostate biopsy. |
| Senstivity | 79.3% |
| Specificity | 72.7% |
| AUC | 0.857 (95% CI, 0.763–0.924) |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Assays |
| Clinical | NA |
| Remarks | Patients with first negative prostate biopsies and consistently high PSA were included in this study. Their PCA3 assays were visualised in two subgroups; ultiparametric MRI for indicating sites suitable for rebiopsy can significantly improve the sensitivity of the PCA3 test in the diagnosis of prostate cancer. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PCA3 |